Baxter Richard B 4/A
4/A · Pelthos Therapeutics Inc. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Pelthos (PTHS) Director Richard B. Baxter Receives 19,108 RSU Award
What Happened
Richard B. Baxter, a director of Pelthos Therapeutics, was granted 19,108 restricted stock units (RSUs) on 2025-07-02. The award is reported as an acquisition (code A) at $0.00 per share (total reported value $0) because these RSUs are compensation rather than a cash purchase.
Key Details
- Transaction date: 2025-07-02 (reported on amended Form 4 filed 2026-04-01).
- Transaction type/code: Grant/Award (A) of 19,108 RSUs at $0.00.
- Shares owned after transaction: Not specified in this amended filing.
- Vesting: RSUs vest in equal quarterly installments over three years, subject to continued service as a director.
- Settlement: Each RSU represents the right to receive one share of common stock and may be settled solely in shares.
- Purpose: RSUs were granted as board compensation under the Issuer’s 2023 Equity Incentive Plan.
- Filing notes: This is an amendment that moves the originally reported grant from Table II to Table I. The amendment was filed ~9 months after the grant date. Exhibit 24 (Power of Attorney) is attached.
Context
RSU grants are a common form of compensation and are primarily a retention mechanism because shares vest over time; they do not reflect an immediate purchase or sale by the insider. Because this is an amended and belated filing, investors may view it as a reporting correction rather than a new trading signal; Form 4s are normally due within two business days of the transaction.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2025-07-02+19,108→ 19,108 total
Footnotes (2)
- [F1]Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.
- [F2]The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.